Cytokines

Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

Retrieved on: 
Tuesday, June 1, 2021
FDA, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Medicine, Cytokines, Growth factors, Blood, Leukocytes, Neutropenia, Spectrum Pharmaceuticals, Granulocyte colony-stimulating factor, Medication, Bone marrow suppression, ROLONTIS, Spectrum Pharmaceuticals, Inc., ROLONTIS, SPECTRUM PHARMACEUTICALS, INC.

I would like to confirm that the FDA has initiated its inspection of the ROLONTIS manufacturing facility, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.

Key Points: 
  • I would like to confirm that the FDA has initiated its inspection of the ROLONTIS manufacturing facility, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
  • ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

OncoSec to Present at the Raymond James Human Health Innovation Conference

Retrieved on: 
Thursday, May 27, 2021
Clinical medicine, Medicine, Virotherapy, Immunology, Cancer immunotherapy, Immunotherapy, Cytokines, Branches of biology, Cytokine, Interleukin, Immune system

PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21st Wednesday, June 23rd, 2021.

Key Points: 
  • PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21st Wednesday, June 23rd, 2021.
  • For those not attending the conference, a replay of the presentation will be available for 90 days in the "Events & Presentations" section of OncoSec's website at https://ir.oncosec.com/events-presentations .
  • OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.
  • OncoSec's lead immunotherapy investigational product candidate TAVO (tavokinogene telseplasmid) enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.

Global Interferons Market Growth to 2030 with Roche, Merck, Bristol-Myers Squibb, Biogen, Bayer, Zydus Cadila, Novartis, Pfizer, Biosidus, and Nanoge Leading the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
General Health, Pharmaceutical, Health, Companies, Life sciences, Industry economics), Cytokines, Antiviral drugs, Novartis, Biogen, Bristol Myers Squibb, Cadila Healthcare, Pfizer, Interferon

The "Interferons Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interferons Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the interferons market are Roche, Merck, Bristol-Myers Squibb, Biogen Inc, Bayer AG, Zydus Cadila, Novartis AG, Pfizer Inc, Biosidus, and Nanoge.
  • The pandemic outbreak of corona virus is expected to drive the growth of interferons market.
  • This is because of the ongoing trials on various drug candidates including interferons as potential therapeutic options for covid-19 treatment.

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232

Retrieved on: 
Monday, May 24, 2021
Interleukins, Cytokines, Immune system, Branches of biology, Medical specialties, Clusters of differentiation

NEWARK, Calif., May 24, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc.(Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232,a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.

Key Points: 
  • NEWARK, Calif., May 24, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc.(Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232,a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.
  • "PN-232 is a second-generation, oral, IL-23 receptor antagonist candidate currently being developed in collaboration with Janssen Research & Development, LLC," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist.
  • PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease.
  • PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates, are in Phase 1 studies.

Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas

Retrieved on: 
Thursday, May 20, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Biology, Immunology, Cytokines, Molecular biology, Animal physiology, Human physiology, Inflammation, Cytokine, Inflammatory cytokine, Plasmid, XT-150, Xalud Therapeutics, XT-150, XALUD THERAPEUTICS

XT-150 is a locally injectable, plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of the cytokine IL-10, to address pathologic inflammation and pain.

Key Points: 
  • XT-150 is a locally injectable, plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of the cytokine IL-10, to address pathologic inflammation and pain.
  • \xe2\x80\x9cThrough localized delivery of IL-10v, we believe XT-150 may have a large-scale impact in reducing inflammation at several somatic and neurologic targets.
  • XT-150 uses a non-integrating therapeutic plasmid DNA that enables local delivery of IL-10v directly to the site of inflammation.
  • IL-10 is a potent anti-inflammatory cytokine that plays a critical role in maintaining homeostasis and reducing inflammation.

Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan

Retrieved on: 
Wednesday, May 19, 2021
Research, Medical devices, Infectious diseases, Hospitals, FDA, Clinical trials, Stem cells, Biotechnology, Health, Science, Branches of biology, Biology, Cytokines, Cytokine, Immunology, Vesicle, Chemokine

This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.

Key Points: 
  • This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.
  • Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer.
  • Specific information included in this press release may change over time and may or may not be accurate after the date of the release.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005143/en/\n'

CD40 Ligand Drugs Development Market Report 2021: T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Pharmaceutical, Clusters of differentiation, Branches of biology, Immune system, Medical specialties, Cytokines, Protein superfamilies, Single-pass transmembrane proteins, CD40, Tumor necrosis factor superfamily, CD154, Cell biology, Trail

b'The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nCD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nCD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics.\n'

MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

Retrieved on: 
Monday, May 17, 2021
Health, Pharmaceutical, Medical specialties, Clinical medicine, Branches of biology, Immunology, Cytokines, Inflammatory cytokine, Tumor necrosis factor, Cytokine, Sjögren syndrome, Inflammation

degree in medical and scientific illustration from the University of Michigan in 1989.

Key Points: 
  • degree in medical and scientific illustration from the University of Michigan in 1989.
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.
  • MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\xce\xb1 blocking drugs, and aging and longevity.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.

Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon™ Delivered Tumor-Focused Interferon Expression

Retrieved on: 
Friday, May 14, 2021
Antiviral drugs, Cytokines, Interferon

The presentation focuses specifically on patients who have undergone a follow-up surgical procedure for their cancer.

Key Points: 
  • The presentation focuses specifically on patients who have undergone a follow-up surgical procedure for their cancer.
  • Concentrations of IFN-\xce\xb1 in the plasma and cerebrospinal fluid of patients remained low, while IFN-\xce\xb1 responses were identified in myeloid cells that infiltrate tumors.
  • A second round of surgery is increasingly considered to have significant benefit in prolonging the lives of patients with GBM.
  • Even with treatment, GBM virtually always recurs, typically resulting in death within the first 15 months from diagnosis.\nInvestor Relator - LifeSci Advisors:\n'

MyMD Pharmaceuticals Schedules Business Update Conference Call

Retrieved on: 
Wednesday, May 12, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Immunology, Cytokines, Clinical medicine, Inflammatory cytokine, Tumor necrosis factor, Cytokine, Inflammation

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.

Key Points: 
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.
  • MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\xce\xb1 blocking drugs, and aging and longevity.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.
  • A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended.